

## **Appendix: Patient recruitment details & study flow**

### **Patient recruitment details:**

Quota:	100 patients; a target of 25 patients every 4 months
Recruitment period:	Launch on 8 December 2017, first-come-first-served
Criteria	-Hong Kong permanent residents -With evidence of recurrent ovarian cancer -Willing to provide tumour DNA and blood samples for the study -Agree to follow up every 4-6 months, for 2 years via phone calls, etc
Contact:	-Interested patients can call 3943-5382 or email <a href="mailto:ovcamut@cuhk.edu.hk">ovcamut@cuhk.edu.hk</a> for pre-screening -All interested parties can visit the website <a href="http://cuhk.edu.hk/proj/ovcamut/">http://cuhk.edu.hk/proj/ovcamut/</a>

### **Study flow:**

- ✧ Interested patients will first be pre-screened and pre-counselled.
- ✧ Once deemed eligible, patients will be invited to the Department of Obstetrics and Gynaecology, Queen Mary Hospital to confirm their consent to participate in this study, and provide blood samples.
- ✧ Patients will have to request tumour specimens from their physicians. Tumour samples will be provided to CUHK for multi-gene sequencing with the Responder Gene Panel, followed by a free professional drug-matching analysis.
- ✧ In 6 - 8 weeks, patients will receive pharmacogenomic study results related to ovarian cancer only, or that related to additional cancer types as a research courtesy.
- ✧ A two-year follow-up for drug choice will be conducted for all consenting patients.